Citadel Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-1,391,302
| Closed | -$8.13M | – | 16077 |
|
|
2022
Q4 | $8.13M | Buy |
1,391,302
+269,873
| +24% | +$1.42M | ﹤0.01% | 3115 |
|
|
2022
Q3 | $7.51M | Buy |
1,121,429
+530,305
| +90% | +$3.21M | ﹤0.01% | 3192 |
|
|
2022
Q2 | $2.49M | Buy |
591,124
+570,731
| +2,799% | +$2.26M | ﹤0.01% | 5118 |
|
|
2022
Q1 | $69K | Sell |
20,393
-54,891
| -73% | -$174K | ﹤0.01% | 12595 |
|
|
2021
Q4 | $237K | Buy |
+75,284
| New | +$251K | ﹤0.01% | 11489 |
|
|
2021
Q3 | – | Sell |
-10,777
| Closed | -$37.8K | – | 15009 |
|
|
2021
Q2 | $45K | Sell |
10,777
-7,613
| -41% | -$32.2K | ﹤0.01% | 13377 |
|
|
2021
Q1 | $92K | Buy |
+18,390
| New | +$149K | ﹤0.01% | 12545 |
|
|
2020
Q2 | – | Sell |
-72,128
| Closed | -$692K | – | 10733 |
|
|
2020
Q1 | $637K | Sell |
72,128
-29,605
| -29% | -$292K | ﹤0.01% | 6089 |
|
|
2019
Q4 | $939K | Sell |
101,733
-42,897
| -30% | -$304K | ﹤0.01% | 5704 |
|
|
2019
Q3 | $850K | Buy |
144,630
+66,517
| +85% | +$706K | ﹤0.01% | 5871 |
|
|
2019
Q2 | $937K | Buy |
78,113
+34,582
| +79% | +$372K | ﹤0.01% | 5795 |
|
|
2019
Q1 | $525K | Buy |
43,531
+4,598
| +12% | +$67.8K | ﹤0.01% | 6711 |
|
|
2018
Q4 | $489K | Sell |
38,933
-37,594
| -49% | -$519K | ﹤0.01% | 6428 |
|
|
2018
Q3 | $1.14M | Sell |
76,527
-24,132
| -24% | -$380K | ﹤0.01% | 5314 |
|
|
2018
Q2 | $1.69M | Sell |
100,659
-61,927
| -38% | -$1.2M | ﹤0.01% | 4358 |
|
|
2018
Q1 | $3.72M | Buy |
162,586
+92,625
| +132% | +$2.06M | ﹤0.01% | 2838 |
|
|
2017
Q4 | $1.81M | Sell |
69,961
-54,718
| -44% | -$1.1M | ﹤0.01% | 3778 |
|
|
2017
Q3 | $1.84M | Sell |
124,679
-350,869
| -74% | -$5.09M | ﹤0.01% | 3503 |
|
|
2017
Q2 | $6.63M | Buy |
+475,548
| New | +$7.01M | 0.01% | 1814 |
|
|
2016
Q2 | – | Sell |
-42,474
| Closed | -$580K | – | 7579 |
|
|
2016
Q1 | $580K | Sell |
42,474
-48,252
| -53% | -$695K | ﹤0.01% | 4197 |
|
|
2015
Q4 | $1.72M | Buy |
90,726
+51,933
| +134% | +$1.13M | ﹤0.01% | 2899 |
|
|
2015
Q3 | $728K | Buy |
+38,793
| New | +$659K | ﹤0.01% | 4252 |
|
|
2015
Q2 | – | Sell |
-19,333
| Closed | -$293K | – | 9196 |
|
|
2015
Q1 | $293K | Sell |
19,333
-40,084
| -67% | -$559K | ﹤0.01% | 5683 |
|
|
2014
Q4 | $791K | Buy |
+59,417
| New | +$767K | ﹤0.01% | 4073 |
|
Citadel Advisors's CNCE Position: Q1 2023 in Review
Citadel Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 1,391,302 shares — an estimated $8.13M sold.
Citadel Advisors first reported a position in CNCE in Q4 2014 and held it in 24 quarters. The position peaked at $8.13M in Q4 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Citadel Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Citadel Advisors sold 1,391,302 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $8.13M.
- Citadel Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q4 2014 and held it in 24 quarters.
- Citadel Advisors's Concert Pharmaceuticals, Inc. position peaked at $8.13M in Q4 2022.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.